分子细胞遗传学分析和试剂开发商KROMATID宣布成功完成800万美元C轮融资，超出增长资本目标-动脉网

KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals

CISION 等信源发布 2025-08-21 02:04



可切换为仅中文







Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies

资金支持KROMATID在基因组分析和基因编辑技术领域的快速发展。

BOULDER, Colo.

博尔德，科罗拉多州

，

Aug. 20, 2025

2025年8月20日

/PRNewswire/ -- KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C funding round, raising a total of

/PRNewswire/ -- KROMATID，下一代基因组结构分析领域的领导者，今天宣布成功完成了其C轮融资，共筹集了

$8 million

800万美元

and surpassing its targeted capital goals. The most recent tranche of the round contributed

并且超过了其目标资本额。本轮融资的最新一部分贡献了

$3.8 million

380万美元

. The round was led by BroadOak Capital Partners, with participation from both existing and new strategic investors.

本轮融资由 BroadOak Capital Partners 领投，现有战略投资者和新战略投资者均有参与。

The capital from this Series C close will fuel expansion of KROMATID's proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy.

本轮 C 轮融资所得将用于推动 KROMATID 专有平台的扩展，以检测染色体结构重排、扩大运营规模满足全球日益增长的需求，并推进与细胞和基因治疗领域的制药及学术领袖的战略合作。

'We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology,'

“我们很高兴能够实现我们的融资目标，这证明了我们的投资者对我们的愿景和我们技术的独特能力充满信心。”

said

说

Jim Chomas

吉姆·乔马斯

, CEO of KROMATID.

，KROMATID首席执行官。

'This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients.'

“这项投资使我们能够更快地扩展规模，进一步创新，并继续提供有助于为患者带来改变生命疗法的基因组洞察。”

'KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry,'

“KROMATID建立了一个差异化平台，可提供精确、高分辨率的基因组完整性分析，这是快速增长的基因和细胞治疗行业中最为迫切的需求之一。”

said

说

Bill Snider

比尔·斯奈德

, Partner at BroadOak Capital Partners.

，BroadOak Capital Partners 合伙人。

'We are proud to continue our partnership as they enter their next phase of growth.'

“我们很自豪能继续我们的合作关系，因为他们进入了下一个增长阶段。”

Over the next 12–18 months, KROMATID plans to deploy this funding to accelerate commercial expansion and enhance automation and throughput in its laboratory operations. The company will also invest in strategic hiring across scientific, operational, and customer-facing teams to meet increasing market demand and solidify its leadership position in genomic structural analysis..

在接下来的 12 到 18 个月里，KROMATID 计划利用这笔资金加速商业扩展，并提升实验室运营中的自动化水平和吞吐量。公司还将战略性地招聘科学、运营和客户面对团队的人才，以满足不断增长的市场需求，并巩固其在基因组结构分析领域的领导地位。

About KROMATID

关于KROMATID

KROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval..

KROMATID 为基因和细胞疗法开发者提供下一代基因组结构分析解决方案，能够以无与伦比的清晰度和分辨率精确检测染色体结构重排。通过结合专有成像和生物信息学能力，KROMATID 支持从发现到监管批准的治疗创新。

About BroadOak Capital Partners

关于布罗德奥克资本合伙人公司

BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has invested in more than 70 life sciences companies including over 35 exits. For more information, visit .

BroadOak Capital Partners 是一家精品金融机构，为生命科学工具、诊断和生物制药服务领域的公司提供直接投资和投资银行服务。BroadOak 已投资了 70 多家生命科学公司，其中超过 35 家已退出。欲了解更多信息，请访问。

www.broadoak.com

。

Media Contact:

媒体联系人:

Amanda Ladas

阿曼达·拉达斯

Global Marketing Manager

全球营销经理

KROMATID

染色单体

aladas@kromatid.com